Gemini Therapeutics (GMTX) Competitors $51.13 -1.83 (-3.46%) As of 07/1/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrendsBuy This Stock GMTX vs. BPMC, VRNA, BBIO, ROIV, RVMD, ELAN, LEGN, GRFS, TLX, and TGTXShould you be buying Gemini Therapeutics stock or one of its competitors? The main competitors of Gemini Therapeutics include Blueprint Medicines (BPMC), Verona Pharma PLC American Depositary Share (VRNA), BridgeBio Pharma (BBIO), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Elanco Animal Health (ELAN), Legend Biotech (LEGN), Grifols (GRFS), Telix Pharmaceuticals (TLX), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry. Gemini Therapeutics vs. Its Competitors Blueprint Medicines Verona Pharma PLC American Depositary Share BridgeBio Pharma Roivant Sciences Revolution Medicines Elanco Animal Health Legend Biotech Grifols Telix Pharmaceuticals TG Therapeutics Gemini Therapeutics (NASDAQ:GMTX) and Blueprint Medicines (NASDAQ:BPMC) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation. Which has higher valuation & earnings, GMTX or BPMC? Blueprint Medicines has higher revenue and earnings than Gemini Therapeutics. Blueprint Medicines is trading at a lower price-to-earnings ratio than Gemini Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGemini TherapeuticsN/AN/A-$71.87M-$1.00-51.13Blueprint Medicines$508.82M16.27-$67.09M-$2.47-51.90 Is GMTX or BPMC more profitable? Gemini Therapeutics has a net margin of 0.00% compared to Blueprint Medicines' net margin of -27.70%. Gemini Therapeutics' return on equity of -38.78% beat Blueprint Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Gemini TherapeuticsN/A -38.78% -35.88% Blueprint Medicines -27.70%-64.60%-17.22% Which has more volatility and risk, GMTX or BPMC? Gemini Therapeutics has a beta of -0.12, suggesting that its stock price is 112% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Do insiders & institutionals believe in GMTX or BPMC? 75.4% of Gemini Therapeutics shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by insiders. Comparatively, 4.2% of Blueprint Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts recommend GMTX or BPMC? Blueprint Medicines has a consensus target price of $128.06, indicating a potential downside of 0.11%. Given Blueprint Medicines' stronger consensus rating and higher probable upside, analysts clearly believe Blueprint Medicines is more favorable than Gemini Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Blueprint Medicines 0 Sell rating(s) 17 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.27 Does the media prefer GMTX or BPMC? In the previous week, Blueprint Medicines had 7 more articles in the media than Gemini Therapeutics. MarketBeat recorded 7 mentions for Blueprint Medicines and 0 mentions for Gemini Therapeutics. Blueprint Medicines' average media sentiment score of 0.96 beat Gemini Therapeutics' score of 0.00 indicating that Blueprint Medicines is being referred to more favorably in the news media. Company Overall Sentiment Gemini Therapeutics Neutral Blueprint Medicines Positive SummaryBlueprint Medicines beats Gemini Therapeutics on 10 of the 16 factors compared between the two stocks. Get Gemini Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GMTX vs. The Competition Export to ExcelMetricGemini TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.22B$782.11M$5.54B$8.87BDividend YieldN/A4.84%5.39%4.10%P/E Ratio-51.131.0926.2319.90Price / SalesN/A219.25413.23113.66Price / CashN/A23.4436.1356.90Price / Book17.695.998.045.38Net Income-$71.87M-$27.64M$3.15B$248.50M7 Day Performance-5.17%-0.07%1.44%2.04%1 Month Performance7.12%6.49%3.62%4.84%1 Year Performance22.85%8.20%34.68%20.23% Gemini Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GMTXGemini TherapeuticsN/A$51.13-3.5%N/A+10.0%$2.22BN/A-51.1330BPMCBlueprint Medicines1.5574 of 5 stars$128.40+0.2%$128.06-0.3%+16.2%$8.28B$508.82M-51.98640High Trading VolumeVRNAVerona Pharma PLC American Depositary Share2.5901 of 5 stars$97.05+2.9%$101.10+4.2%+482.7%$8.03B$42.28M-48.5330Positive NewsAnalyst ForecastBBIOBridgeBio Pharma4.7146 of 5 stars$42.17+1.1%$56.67+34.4%+71.9%$7.92B$221.90M-11.95400Analyst ForecastInsider TradeROIVRoivant Sciences1.9443 of 5 stars$11.50+0.4%$17.50+52.2%+3.9%$7.78B$29.05M-46.00860RVMDRevolution Medicines4.4993 of 5 stars$40.04+1.0%$67.08+67.5%-0.5%$7.39B$11.58M-10.01250Analyst RevisionGap UpELANElanco Animal Health2.3429 of 5 stars$13.36-0.7%$15.17+13.5%+5.1%$6.68B$4.44B18.059,000Analyst ForecastLEGNLegend Biotech3.4996 of 5 stars$33.85-0.4%$76.20+125.1%-19.7%$6.25B$627.24M-57.372,609News CoveragePositive NewsAnalyst ForecastGRFSGrifols4.137 of 5 stars$8.37-4.6%$10.30+23.1%+40.2%$6.03B$7.81B7.1523,822TLXTelix PharmaceuticalsN/A$16.39-4.4%$22.00+34.2%N/A$5.80B$516.72M0.00N/AGap DownHigh Trading VolumeTGTXTG Therapeutics3.7706 of 5 stars$36.56+1.5%$40.80+11.6%+98.2%$5.72B$329M152.33290 Related Companies and Tools Related Companies Blueprint Medicines Alternatives Verona Pharma PLC American Depositary Share Alternatives BridgeBio Pharma Alternatives Roivant Sciences Alternatives Revolution Medicines Alternatives Elanco Animal Health Alternatives Legend Biotech Alternatives Grifols Alternatives Telix Pharmaceuticals Alternatives TG Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GMTX) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredMake 22x more from this summer’s Bitcoin boomBitcoin is on fire again. Wall Street’s piling in. ETFs are smashing volume records. And regular investors ...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemini Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemini Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
